New eye drops promise clearer vision without glasses: A new generation of prescription eye drops is offering adults an alternative to reading glasses, promising sharper near vision for much of the day. But while the treatment represents a significant development in eye care, it does not eliminate tired eyes, and users need to understand its limitations and potential risks.
The product is VIZZ, an eye drop containing aceclidine that received approval from the U.S. Food and Drug Administration (FDA) in July 2025. It is designed to treat presbyopia, an age-related condition that makes it increasingly difficult to focus on nearby objects, such as reading or working on a computer.
According to the FDA, the treatment was approved following clinical trials demonstrating improvements in near vision. The manufacturer, LENZ Therapeutics, says the effects can begin within 30 minutes and last for up to 10 hours. Results vary between individuals.
How do the eye drops work?
VIZZ works by constricting the pupil, creating a pinhole effect that increases the eye’s depth of focus. This allows more nearby objects to appear sharp without directly reversing the underlying changes in the eye‘s lens.
Presbyopia commonly develops after age 40 as the natural lens gradually loses flexibility. People may notice difficulty reading smartphone screens, menus, books, or small print, even when their distance vision remains relatively good.
The new drops offer a temporary way to manage these symptoms without surgery or reading glasses. However, they do not permanently restore the lens’ flexibility, and the effects wear off.
Importantly, presbyopia is not the same as myopia, or short-sightedness. People with myopia struggle to see distant objects clearly, whereas presbyopia primarily affects close-up focusing. VIZZ is approved for presbyopia, not as a treatment specifically intended to correct myopia.
What do clinical trials show?
The FDA based its approval on three clinical studies. Two main efficacy trials, CLARITY-1 and CLARITY-2, included 466 participants with presbyopia and evaluated the treatment over 42 days. A separate study assessed longer-term safety.
The results supported improvements in near visual acuity, with benefits measurable within the first 30 minutes and potentially lasting up to 10 hours.
Nevertheless, the treatment should not be viewed as a universal replacement for glasses. The degree of improvement varies, and some patients may continue to need corrective lenses for certain activities. The studies also do not establish that the drops prevent or reverse the biological causes of presbyopia.
Side effects and potential drawbacks
Although most reported adverse reactions in clinical trials were mild and temporary, the drops are not risk-free.
According to the prescribing information published by the U.S. National Library of Medicine’s DailyMed database, the most common adverse reactions included:
- Eye irritation: Reported by 20% of trial participants.
- Temporary dim or dark vision: Reported by 16%.
- Headaches: Reported by 13%.
- Eye redness: Also reported in a smaller proportion of participants.
These percentages reflect clinical-trial findings and do not predict exactly how an individual will respond. A more serious concern involves rare reports of retinal tears and retinal detachment associated with pupil-constricting eye medications. The prescribing information recommends a retinal examination before treatment and immediate medical attention if users experience sudden flashes of light, a new onset of floaters, or vision loss.
Temporary changes in vision may also make driving or operating machinery unsafe. Particular caution is advised when driving at night or performing activities in poorly lit environments. People with a history of iritis, an inflammatory eye condition, should discuss the risks with their eye specialist.
Precautions before using VIZZ
VIZZ is a prescription medication in the United States, so patients should consult an eye-care professional before using it. An eye examination can establish whether their symptoms are caused by presbyopia or another condition requiring different treatment.
Users should follow the prescribed dosing instructions, avoid touching the vial tip to the eye or other surfaces, and discard the single-dose vial after opening. Contact lenses should be removed before administration and may be reinserted after 10 minutes, according to the prescribing information.
Anyone experiencing sudden visual disturbances should seek urgent medical assessment rather than assuming the symptoms are a routine side effect.
Can eye drops replace glasses?
For some adults with presbyopia, VIZZ offers a convenient, temporary option for reading and other close-up activities. Its duration of action could reduce the need to reach for reading glasses throughout the day.
However, it is not a cure for age-related vision changes, does not suit everyone, and is not a dedicated treatment for myopia. Cost, availability, and the need for a prescription may also affect whether patients choose it.
The bottom line is that these eye drops represent progress in managing age-related near-vision problems, but a professional assessment remains essential. Patients should weigh the potential convenience against the side effects and remember that established options, including glasses and contact lenses, remain effective ways to correct refractive errors.